✦ LIBER ✦

Trilostane with hydrocortisone in treatment of metastatic breast cancer

✍ Scribed by Ping S. Chu; Aman U. Buzdar; Gabriel N. Hortobagyi

Publisher: Springer US
Year: 1989
Tongue: English
Weight: 344 KB
Volume: 13
Category: Article
ISSN: 0167-6806
DOI: 10.1007/bf01806523

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Trilostane in the treatment of advanced

Trilostane in the treatment of advanced breast cancer

✍ C. G. Beardwell; A. C. Hindley; P. M. Wilkinson; I. D. H. Todd; G. G. Ribeiro; d 📂 Article 📅 1983 🏛 Springer 🌐 English ⚖ 284 KB

Treatment of metastatic breast cancer wi

Treatment of metastatic breast cancer with aminoglutethimide

✍ R. F. Asbury; R. F. Bakemeier; E. Fölsch; C. S. McCune; E. Savlov; J. M. Bennett 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 504 KB

Herceptin in the treatment of metastatic

Herceptin in the treatment of metastatic breast cancer

✍ G. Konecny; M. Untch; M. Pegram 📂 Article 📅 1999 🏛 Springer 🌐 German ⚖ 120 KB

Optimizing the treatment of metastatic b

Optimizing the treatment of metastatic breast cancer

✍ Julie R. Gralow 📂 Article 📅 2005 🏛 Springer US 🌐 English ⚖ 193 KB

Gemcitabine for palliative treatment in

Gemcitabine for palliative treatment in metastatic breast cancer

✍ D. Lüftner; B. Flath; C. Akrivakis; R. Grunewald; H.-G. Mergenthaler; K. Possing 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 126 KB

Oral medroxyprogesterone in the treatmen

Oral medroxyprogesterone in the treatment of metastatic breast cancer

✍ Takuma Nemoto; Jashbha1 Patel; Dutzu Rosner; Thomas L. Dao 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB

In 47 postmenopausal women with evaluable breast cancer, oral medroxyprogesterone acetate (MPA) was given at a daily dose level of 400 mg. Patients with negative estrogen receptors, poor performance status , or nonresponse to previous endocrine therapy were excluded from this study. There were 25 (